459 related articles for article (PubMed ID: 29183390)
1. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
[TBL] [Abstract][Full Text] [Related]
3. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.
Lien EA; Søiland H; Lundgren S; Aas T; Steen VM; Mellgren G; Gjerde J
Breast Cancer Res Treat; 2013 Sep; 141(2):243-8. PubMed ID: 23996142
[TBL] [Abstract][Full Text] [Related]
5. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
[TBL] [Abstract][Full Text] [Related]
6. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
7. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
Mbavha BT; Thelingwani RS; Chikwambi Z; Nyakabau AM; Masimirembwa C;
Br J Clin Pharmacol; 2023 Oct; 89(10):3209-3216. PubMed ID: 37337448
[TBL] [Abstract][Full Text] [Related]
10. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
Abraham JE; Maranian MJ; Driver KE; Platte R; Kalmyrzaev B; Baynes C; Luccarini C; Shah M; Ingle S; Greenberg D; Earl HM; Dunning AM; Pharoah PD; Caldas C
Breast Cancer Res; 2010; 12(4):R64. PubMed ID: 20731819
[TBL] [Abstract][Full Text] [Related]
12. Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable?
Gusella M; Pasini F; Corso B; Bertolaso L; De Rosa G; Falci C; Modena Y; Barile C; Da Corte Z D; Fraccon A; Toso S; Cretella E; Brunello A; Modonesi C; Segati R; Oliani C; Minicuci N; Padrini R;
Pharmacol Res Perspect; 2020 Oct; 8(5):e00646. PubMed ID: 32813313
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
14. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.
Hertz DL; Kidwell KM; Hilsenbeck SG; Oesterreich S; Osborne CK; Philips S; Chenault C; Hartmaier RJ; Skaar TC; Sikora MJ; Rae JM
Breast Cancer Res Treat; 2017 Nov; 166(1):277-287. PubMed ID: 28730340
[TBL] [Abstract][Full Text] [Related]
16. Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen.
Helland T; Naume B; Hustad S; Bifulco E; Kvaløy JT; Saetersdal AB; Synnestvedt M; Lende TH; Gilje B; Mjaaland I; Weyde K; Blix ES; Wiedswang G; Borgen E; Hertz DL; Janssen EAM; Mellgren G; Søiland H
Mol Oncol; 2021 Apr; 15(4):957-967. PubMed ID: 33252186
[TBL] [Abstract][Full Text] [Related]
17. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
[TBL] [Abstract][Full Text] [Related]
18. A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
Johansson H; Gandini S; Serrano D; Gjerde J; Lattanzi M; Macis D; Guerrieri-Gonzaga A; Aristarco V; Mellgren G; Lien E; DeCensi A; Bonanni B
Breast Cancer Res Treat; 2016 Aug; 159(1):97-108. PubMed ID: 27484880
[TBL] [Abstract][Full Text] [Related]
19. Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer.
Puszkiel A; Arellano C; Vachoux C; Evrard A; Le Morvan V; Boyer JC; Robert J; Delmas C; Dalenc F; Debled M; Venat-Bouvet L; Jacot W; Dohollou N; Bernard-Marty C; Laharie-Mineur H; Filleron T; Roché H; Chatelut E; Thomas F; White-Koning M
Clin Pharmacol Ther; 2021 May; 109(5):1244-1255. PubMed ID: 33047329
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
